Ferring Demonstrates Effectiveness of a Treat-to-Target Approach in Mild-to-Moderate Ulcerative Colitis in First Major Study
1.10.2024 10:15:00 EEST | Business Wire | Press release
Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) approach based on faecal calprotectin (FC) in patients with mild-to-moderate ulcerative colitis (M2M UC). These results have been published in the Journal of Clinical Medicine.1
UC is a chronic, inflammatory bowel condition which can cause recurring bloody diarrhoea, stomach pain and extreme tiredness.4 Of those living with UC, over 85% have mild-to-moderate disease.5,6,7 Usually 5-ASA compounds are the first-line therapy for people with M2M UC, followed by a stepwise treatment approach in case of non-response or intolerance. There is currently limited guidance on timely escalation and de-escalation of therapies.
OPTIMISE was the first major study to investigate whether a T2T approach based on monitoring of non-invasive parameters, such as clinical symptoms and FC, can provide a significantly higher benefit for patients with M2M UC versus an entirely symptom-based approach. “The OPTIMISE study represents another milestone in the management of M2M UC and demonstrates Ferring’s continued commitment to science and improving the lives of people with inflammatory bowel disease (IBD),” said Pierre-Yves Berclaz, Chief Science & Medical Officer, Ferring Pharmaceuticals.
Results from OPTIMISE, a pragmatic, randomised controlled study, showed that people who had their 5-ASA/mesalazine treatment optimised (with or without steroids) by following the T2T approach had a 17–22% advantage at achieving combined endoscopic and clinical remission over a symptoms-only based approach. For the primary endpoint of Mayo Endoscopic Score (MES)=0 at 12 months, no significant difference was found, however it was noted by the investigators that the COVID-19 pandemic negatively impacted the amount of evaluable data.1
“OPTIMISE has provided the first real-world evidence that a T2T approach can help people living with IBD to achieve long-lasting remission and have a greater quality of life,” said Kristine Paridaens, Senior Medical Director, Gastroenterology, Ferring Pharmaceuticals.
A T2T approach has been advocated by the International Organisation for the Study of IBD (IOIBD).In their Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Consensus they recommended resolution of clinical signs of disease activity and endoscopic remission as the optimal targets.2 This was further refined in STRIDE-II to include symptomatic relief and normalisation of serum and faecal markers as short-term targets for all therapies.3
The OPTIMISE results coincide with an international expert consensus focusing on the practical management of M2M UC, which was published in Expert Review of Gastroenterology and Hepatology.8 Professor Silvio Danese, a co-author of the Consensus and Principle Investigator of the OPTIMISE study, said, “The OPTIMISE study provides real-world evidence of the effectiveness of a T2T approach based on FC monitoring and how its implementation in clinical practice will allow clinicians to tightly monitor disease activity and promptly adapt treatment, helping to avoid complications and disease progression and enabling patients to achieve better disease control.”
To learn more, register here to attend the free ‘New avenues in mild-to-moderate UC treatment optimisation’ webinar on 8th October, 2024. Principal Investigators of the OPTIMISE study, Prof Silvio Danese and Prof Laurent Peyrin-Biroulet, will provide an expert overview of the results and the implications for clinical practice. The webinar is intended for healthcare professionals only.
About the OPTIMISE study1
OPTIMISE was a European-based, multi-centre, randomised (1:1) controlled study of 250 patients with M2M UC (global Mayo score 2–6) treated with ≤2.4g/day 5-aminosalicylic acid that compared the effectiveness of two management strategies with (T2T arm) and without (reference arm) FC home monitoring over 12 months follow-up. Treatment was optimised (escalated or de-escalated) in the T2T arm using FC values and clinical symptoms (PRO-2), whilst the reference arm used only PRO-2. In both arms, therapy was optimised in line with current ECCO guidelines for UC, including maximal doses of 5-ASA (oral and rectal).
A total of 193 patients completed the study despite the acknowledged impact of the COVID-19 pandemic on all clinical studies conducted during that time. Reduced patient contact during the COVID-19 period also affected the availability of data for analysis. For the primary endpoint of MES=0 at 12 months, there was no significant difference between arms, when patients with missing values were classified as non-responders. A subsequent analysis using Monte Carlo Markov Chain (MCMC) imputation found a numerical advantage for the T2T arm over the reference arm for the primary endpoint (37.0% vs 33.4%, respectively). The secondary endpoints, including clinical symptomatology and quality of life, were similarly impacted by missing data, but again displayed numerical superiority for MES≤1, RB=0 and SF≤1 at 12 months when using MCMC imputation.
A logistic regression analysis pooling results for MES, SF and RB at 12 months, using data derived from MCMC imputation, found a statistically significant advantage for the T2T arm over the reference arm (p<0.001). When these endpoints were combined in a fixed effects meta-analysis, the combined endpoint of MES=0, RB=0 and SF≤1 at 12 months was achieved at a significantly higher rate in the T2T than the reference arm (effect size [ES]: 0.17, 95% CI 0.02, 0.32; p<0.05). A similar result was obtained for MES≤1, RB=0 and SF≤1 at 12 months (ES: 0.22; 95% CI 0.07, 0.37; p<0.05).
References
1 Danese S, Fiorino G, Vicaut E, et al. Pragmatic Randomised Controlled Study to Assess the Effectiveness of Two Patient Management Strategies in Mild to Moderate Ulcerative Colitis – the OPTIMISE study. J Clin Med 2024;13:5147.
2 Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol 2015;110:1324–38.
3 Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021;160:1570–83.
4 NHS. Ulcerative colitis. Available at: https://www.nhs.uk/conditions/ulcerative-colitis/. Last accessed: September 2024.
5 Raine T, Bonovas S, Kucharzik T, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis. 2022;16(1):2-17.
6 Fumery M, Singh S, Dulai PS, et al. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. 2018;16(3):343-356.e3.
7 CCDS Pentasa All formulations. Version 18. 10 December 2022.
8 D'Amico F, Magro F, Dignass A, et al. Practical management of mild-to-moderate ulcerative colitis: an international expert consensus. Expert Rev Gastroenterol Hepatol 2024;18:421–30.
© 2024 Ferring. Ferring and the Ferring Pharmaceuticals logo are trademarks of the Ferring group of companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240930008755/en/
Contacts
Matthew Worrall
Director, Corporate Communications, Ferring
+44 7442 271 811
Matthew.Worrall@ferring.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Plural Raises €1bn to Back the Frontier Founders Building a New Europe16.11.2026 11:00:00 EET | Press release
Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US and China, leaving Europe a customer rather than a creator. That has cost the continent prosperity and bargaining power. Rapid technological change now gives Europe a chance to catch up, and Plural believes the continent has the founders, research and momentum to build many more global companies of its own. Global companies, built from Europe When Plural launched in 2022, frontier founders working on defence, energy, space and AI infrastructure in Europe struggled to raise capital. Plural’s partners backed startups in these sectors early, and Plu
SES and ITU Expand Partner2Connect Digital-learning Initiative to 30 African Schools16.11.2026 10:36:00 EET | Press release
SES, a leading space solutions company, announced progress on its commitment to the International Telecommunication Union's (ITU) Partner2Connect Digital Coalition, through which the company is connecting 30 schools across Malawi, Burundi, Zambia, and Zimbabwe by the end of 2026. The initiative, developed in cooperation with the ITU Telecommunication Development Bureau, aims to expand access to digital education and online resources for an estimated 20,000 to 30,000 students and teachers in underserved and remote communities. Through SES’s solutions, the coalition has given students and educators access to online learning platforms, teacher-training resources and collaboration tools. These resources help schools strengthen digital skills and expand learning opportunities to allow students better participate in the future economy. “Digital inclusion depends on more than reaching remote locations. It requires partners that can translate commitments into connectivity that communities can
Regnology and ActiveViam Partner to Bring the Same Granular, Explainable Risk Intelligence to Banks and Their Supervisors16.11.2026 10:00:00 EET | Press release
Regnology, a leading global technology provider at the intersection of regulatory reporting, risk management, finance, and supervisory technology, today announced a strategic partnership with ActiveViam, the provider of Atoti, the AI-native enterprise risk intelligence platform for capital markets. The partnership embeds Atoti as the real-time risk aggregation and analytics engine in Regnology Risk Hub, and will extend it to supervisory authorities through Regnology Supervisory Hub. Regnology is the only provider whose offering serves both the regulated and their regulators, with more than 15,000 financial institutions and more than 100 authorities as clients. Markets and depositors now move within days, and the questions that follow rarely fit a predefined report. During the 2023 market turmoil, supervisors faced significant delays in accessing liquidity data and relied on daily calls with bank treasurers, according to the European Banking Authority. Banks and supervisors share the co
Don’t Let Europe’s Nicotine Black Market Go Unchecked16.11.2026 09:06:00 EET | Press release
On the UN International Day against Transnational Organised Crime, Crime Stoppers International (CSI) launched Don’t let it go unchecked, a campaign asking the public to help break Europe’s black market in vapes and nicotine pouches by reporting illegal sellers anonymously. This matters more than ever. Illegal vapes and nicotine pouches are flooding into Europe. The sellers don’t care how they’re made or who buys them, and don’t pay taxes. Nobody knows who's behind them, except the criminal networks cashing in. The illegal trade in nicotine products is funding the same criminal networks that traffic fake medicine, illicit drugs and weapons, and putting untested products into the hands of children. Hayley van Loon, CEO of Crime Stoppers International, said: “It’s just a vape. It’s just a pouch. That is exactly what the criminals selling them want you to think. Nobody knows what’s in these products. They’re made in illegal factories with no safety standards and sold to anyone, including
Sofinnova Partners Closes €725M Crossover II Fund16.11.2026 09:00:00 EET | Press release
Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Crossover II at €725 million ($815 million USD). The fund exceeded its original target, reflecting growing confidence in Sofinnova’s strategy of backing late-stage life sciences companies with the potential to become global leaders. Sofinnova Crossover II will focus primarily on European clinical-stage biopharma and medtech companies seeking capital to advance toward commercialization. It will also invest in best-in-class companies in the United States and other international markets. Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said: "The scale of this fund reflects both the maturity of the European life sciences ecosystem and the rising demand for capital that can help companies to reach global markets. Europe is producing a growing number of world-class life sciences companies, and we believ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom